bisphosphocin nu-3

Nucleic acidexperimental

Clinical trial activity

3 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2016 (NCT02737722)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • bisphosphocin nu-3
  • bisphosphocin nu-3

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06020235Phase 2Nov 30, 2023Lakewood-Amedex Inc
NCT05276401Phase 2Mar 11, 2022Lakewood-Amedex Inc, PrimeVigilance LTD, Professional Education and Research Institute
NCT02737722Phase 1/Phase 2 (Phase 2)Apr 1, 2016Lakewood-Amedex Inc
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Lakewood-Amedex IncFor profit3312016
PrimeVigilance LTDFor profit1012022
Professional Education and Research InstituteFor profit1012022
3 organizations
Page 1 / 1